Janssen picks up Roche rejects from Evotec
This article was originally published in Scrip
Evotec has exclusively licensed to Janssen Pharmaceuticals a portfolio of small-molecule selective NMDA antagonists for development against depression. The portfolio had been licensed to Roche, which terminated the agreement in 2011.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.